FY21 revenues at £18.3m were in line with the guidance issued at the trading statement in February of £18-20m and represent growth of 10% YoY, despite the impact of the pandemic on core testing revenues. £3.2m of revenues derived from Covid-19 testing, providing a useful hedge against those pandemic-related headwinds, and Yourgene is broadening its routes to market, with a number of partners and frameworks signed in recent weeks. The new year looks to have started positively, with delays in cont ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line trading update, positive outlook
- Published:
29 Apr 2021 -
Author:
Chris Glasper -
Pages:
3
FY21 revenues at £18.3m were in line with the guidance issued at the trading statement in February of £18-20m and represent growth of 10% YoY, despite the impact of the pandemic on core testing revenues. £3.2m of revenues derived from Covid-19 testing, providing a useful hedge against those pandemic-related headwinds, and Yourgene is broadening its routes to market, with a number of partners and frameworks signed in recent weeks. The new year looks to have started positively, with delays in cont ....